Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid diseaseLivius Penter, Catherine J. Wu, Yang Liu et al.|Blood|2023Cited by 51
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I TrialEdwin R. Parra, Cara Haymaker, Ignacio I. Wistuba et al.|Clinical Cancer Research|2024Cited by 42
Tutorial: integrative computational analysis of bulk RNA-sequencing data to characterize tumor immunity using RIMALin Yang, X. Shirley Liu, Jin Wang et al.|Nature Protocols|2023Cited by 21
Mechanisms of Response and Resistance to Combination Decitabine and Ipilimumab for Transplant Naïve and Post-Transplant AML/MDSLivius Penter, Catherine J. Wu, Yang Liu et al.|Blood|2022Cited by 2
Supplementary Table 5 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I TrialEdwin R. Parra, Cara Haymaker, Jiexin Zhang et al.|Unknown|2024Cited by 0